Epoch Investment Partners Inc. Purchases 46,772 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Epoch Investment Partners Inc. increased its stake in Edwards Lifesciences by 15.4%, now holding 350,973 shares worth approximately $25.4 million after acquiring an additional 46,772 shares.
• Multiple institutional investors, including Jennison Associates LLC and Brown Advisory Inc., have also raised their positions significantly, reflecting strong institutional interest with 79.46% ownership of the company's stock.
• Analysts have raised their price targets for Edwards Lifesciences, with JPMorgan Chase setting a target of $85, and the stock currently has a consensus rating of "Moderate Buy" with an average price target of $85.90.

Epoch Investment Partners Inc. grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 15.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 350,973 shares of the medical research company's stock after buying an additional 46,772 shares during the period. Epoch Investment Partners Inc. owned approximately 0.06% of Edwards Lifesciences worth $25,439,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of EW. Quantbot Technologies LP bought a new position in Edwards Lifesciences during the 1st quarter worth approximately $26,000. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the fourth quarter worth $27,000. SouthState Corp bought a new position in shares of Edwards Lifesciences during the first quarter worth $27,000. Global X Japan Co. Ltd. grew its holdings in shares of Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after buying an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC increased its position in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,014 shares of company stock worth $1,698,844 over the last three months. Insiders own 0.34% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on EW. Barclays lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Mizuho lifted their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a report on Friday, July 25th. The Goldman Sachs Group reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Stifel Nicolaus raised their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Finally, Wells Fargo & Company upped their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a report on Thursday, August 7th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $85.90.

Edwards Lifesciences Stock Up 0.3%

NYSE EW traded up $0.25 during trading on Monday, hitting $81.48. The stock had a trading volume of 2,743,784 shares, compared to its average volume of 3,802,425. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company's 50-day moving average price is $78.31 and its two-hundred day moving average price is $75.01. The company has a market capitalization of $47.84 billion, a PE ratio of 11.72, a P/E/G ratio of 3.92 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the business earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.